E S Robinson1, R Feng, J Okawa, V P Werth. 1. Veteran Affairs Medical Center, Philadelphia, PA, U.S.A.; Department of Dermatology, University of Pennsylvania, 1 Convention Avenue, Philadelphia, PA, 19104, U.S.A.
Abstract
BACKGROUND: Cutaneous dermatomyositis (DM) disease activity is associated with decreased quality of life. OBJECTIVES: To assess if an improvement in quality of life, as measured by the Skindex-29 and patient-reported itch and pain on a 10-point visual analogue scale (VAS), correlated with an improvement in cutaneous DM disease activity. METHODS: Patients with a completed cutaneous DM disease area and severity index [Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)] at two visits separated by at least 2 months were classified into responder (n = 15) and nonresponder (n = 30) groups according to the point change in the CDASI activity scores between visits. Responders had at least a four-point improvement in CDASI activity, indicating clinically relevant improvement. RESULTS: The change from baseline to the follow-up visit of the Skindex-29 subscale scores for the responders vs. the nonresponders were significantly different for emotions (P < 0·01), functioning (P < 0·01) and symptoms (P < 0·01). The change in VAS score between responders and nonresponders was also significant for itch (P = 0·01) and pain (P = 0·04). There was no significant difference between the groups in terms of disease subtype, sex, race, age, treatment for DM, smoking history or a history of malignancy within 5 years of a diagnosis of DM. CONCLUSIONS: This is the first study to demonstrate that the quality of life of patients with DM improved as their cutaneous disease activity decreased.
BACKGROUND:Cutaneous dermatomyositis (DM) disease activity is associated with decreased quality of life. OBJECTIVES: To assess if an improvement in quality of life, as measured by the Skindex-29 and patient-reported itch and pain on a 10-point visual analogue scale (VAS), correlated with an improvement in cutaneous DM disease activity. METHODS:Patients with a completed cutaneous DM disease area and severity index [Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)] at two visits separated by at least 2 months were classified into responder (n = 15) and nonresponder (n = 30) groups according to the point change in the CDASI activity scores between visits. Responders had at least a four-point improvement in CDASI activity, indicating clinically relevant improvement. RESULTS: The change from baseline to the follow-up visit of the Skindex-29 subscale scores for the responders vs. the nonresponders were significantly different for emotions (P < 0·01), functioning (P < 0·01) and symptoms (P < 0·01). The change in VAS score between responders and nonresponders was also significant for itch (P = 0·01) and pain (P = 0·04). There was no significant difference between the groups in terms of disease subtype, sex, race, age, treatment for DM, smoking history or a history of malignancy within 5 years of a diagnosis of DM. CONCLUSIONS: This is the first study to demonstrate that the quality of life of patients with DM improved as their cutaneous disease activity decreased.
Authors: P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245
Authors: C O Anyanwu; D F Fiorentino; L Chung; C Dzuong; Y Wang; J Okawa; K Carr; K J Propert; V P Werth Journal: Br J Dermatol Date: 2015-08-11 Impact factor: 9.302
Authors: L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt Journal: Ann Intern Med Date: 1999-03-16 Impact factor: 25.391
Authors: Jennifer L Hundley; Christie L Carroll; Wei Lang; Beverly Snively; Gil Yosipovitch; Steven R Feldman; Joseph L Jorizzo Journal: J Am Acad Dermatol Date: 2005-12-02 Impact factor: 11.527
Authors: Z Shirani; M J Kucenic; C L Carroll; A B Fleischer; S R Feldman; G Yosipovitch; J L Jorizzo Journal: Clin Exp Dermatol Date: 2004-05 Impact factor: 3.470
Authors: B Drouet; X Le Loët; O Vittecoq; G Nouvet; A Genevois; P Lauret; P Tron; J F Menard; P Czernichow; J F Muir; E Mallet Journal: Rev Rhum Engl Ed Date: 1996-05
Authors: Josef Symon S Concha; Aikaterini Patsatsi; Ann Marshak-Rothstein; Ming-Lin Liu; Animesh A Sinha; Lela A Lee; Joseph F Merola; Ali Jabbari; Johann E Gudjonsson; François Chasset; Paul Jarrett; Benjamin Chong; Lisa Arkin; Anthony P Fernandez; Marzia Caproni; Steven A Greenberg; Hee Joo Kim; David R Pearson; Alisa Femia; Ruth Ann Vleugels; David Fiorentino; Manabu Fujimoto; Joerg Wenzel; Victoria P Werth Journal: J Invest Dermatol Date: 2018-09-19 Impact factor: 8.551